Molecular-genetic markers for prediction of radiotherapy response in head and neck cancer
Currently, there is no clinical marker which allows a pre-therapeutic selection of patients with head and neck tumors that would profit more from the conservative therapy or primary surgery, respectively. In this project, we will focus on this "First Therapy Dilemma" by developing the Ionizing Radiation Induced Foci staining method to evaluate the radiosensitivity of individual tumors. The relative radioresistance of tumors will be assessed by comparing their repair capacity and cell death with peripheral blood lymphocytes isolated from the same patient or with the “healthy” tissue adjacent to the tumor. This method may reveal the patients hypersensitive to gamma-rays, estimate the maximum acceptable radiotherapy dose, assess a responsiveness of tumors to replication stress, and elucidate effectiveness of alternative irradiation regimes as well as provide a tool to select patients profitable from proton therapy. The main aim of this project is then development of a cost-efficient, fast, robust, and easy to perform diagnostics method with a large room for automation.
Total number of publications: 25